Mitoxantrone Injection and Eltrombopag: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mitoxantrone Injection
Eltrombopag
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased mitoXANTRONE exposure and an increased risk of mitoXANTRONE-related adverse reactions
Interaction Deep Dive
Exert caution if eltrombopag is coadministered with mitoXANTRONE (BCRP substrate) as it may result in increased mitoXANTRONE exposure. If concomitant use is required, monitor patients closely for signs and symptoms of excessive mitoXANTRONE exposure. Consider reducing mitoXANTRONE dose if necessary. In a drug interaction study, rosuvastatin (BCRP substrate) AUC(0 to inf) and Cmax increased by 55% and 103%, respectively, following coadministration of eltrombopag (BCRP inhibitor) 75 mg/day for 5 days and a single dose of rosuvastatin 10 mg in a clinical study1.
Why it happens (mechanism)
Inhibition of BCRP-mediated efflux transport of mitoXANTRONE
Literature reports
1 report — tap to read
a) In a drug interaction study, rosuvastatin (BCRP substrate) AUC(0 to inf) and Cmax increased by 55% and 103%, respectively, following coadministration of eltrombopag (BCRP inhibitor) 75 mg/day for 5 days and a single dose of rosuvastatin 10 mg in a clinical study 1.
Common questions
Can I take Mitoxantrone Injection and Eltrombopag together?
Increased mitoXANTRONE exposure and an increased risk of mitoXANTRONE-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mitoxantrone Injection and Eltrombopag interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Mitoxantrone Injection or Eltrombopag need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: PROMACTA(R) oral tablets, oral suspension, eltrombopag oral tablets, oral suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2025. DailyMed
Keep reading about Mitoxantrone Injection
Keep reading about Eltrombopag
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist